Important Safety Information
Indications for use
The SPRINT® Peripheral Nerve Stimulation (PNS) System is indicated for up to 60 days in the back and/or extremities for:
- Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain
- Symptomatic relief of post-traumatic pain
- Symptomatic relief of post-operative pain
The Sprint PNS System is not intended to treat pain in the craniofacial region.
Use of the SPRINT® PNS System is contraindicated for:
- Patients who have a Deep Brain Stimulation (DBS) system
- Patients who have an implanted active cardiac implant (e.g. pacemaker or defibrillator)
- Patients who have any other implantable neuro-stimulator whose stimulus current pathway may overlap with that of the SPRINT System
- Patients who require Magnetic Resonance Imaging (MRI). The SPRINT® MicroLead and other SPRINT components must be removed from the body before an MRI
- Patients who have a tape or adhesive allergy
The most common device-related adverse events reported in clinical studies included skin irritation and erythema. The majority of the device-related adverse events were resolved with little to no intervention within a few days, and none were classified as serious.
MRI safety information
The SPRINT PNS System is MR unsafe.
All MRI procedures, no matter the anatomic site, are contraindicated for patients with the Sprint PNS System. Exposure can cause tissue heating and injury or unwanted stimulation. Pull out the lead and remove all other system components from the patient before an MRI examination is performed. In the case of a lead fracture beneath the skin resulting in a retained lead remnant, an MRI examination is safe to perform under the conditions described in the MR Conditional statement below.
A retained lead remnant ONLY is MR conditional.
Non-clinical testing has demonstrated that a Retained Lead Remnant ONLY is MR Conditional. A patient with a retained lead remnant can be safely scanned in an MR system meeting the following conditions:
- Static magnetic field of 1.5 Tesla
- Maximum spatial field gradient of 2,000-Gauss/cm (20 T/m)
- Maximum MR system reported whole body averaged specific absorption rate (SAR) of 2 W/kg (Normal Operating Mode)
Under the scan conditions defined above, the retained lead remnant is expected to produce a maximum temperature rise of less than 3.3°C after 15 minutes of continuous scanning.
In non-clinical testing, the image artifact caused by a retained lead remnant extends less than 7mm from the remnant when imaged with a gradient echo pulse sequence and a 1.5 T MRI system.
Note: There should be no section of lead visible above the skin.
Note: If a lead is placed in an individual with an existing retained lead remnant, the new lead should not be placed in a location where it could touch the original lead remnant. During MRI, two lead remnants touching each other can result in an increase in temperature of the lead remnants and surrounding tissue where they touch.